SpectraCure AB

As of June 30, 2026, SpectraCure AB carries a market capitalization of 31.38M, placing it among publicly traded companies globally. Its enterprise value stands at 32.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, SpectraCure AB has 735.49M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, SpectraCure AB maintains a current ratio of 0.79, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.53, indicating elevated leverage, while an interest coverage ratio of -14.36 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, SpectraCure AB posted a negative return on equity (ROE) of -48.61, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -38.83, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 13.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, SpectraCure AB recorded 41,000.00 in income tax expense. The company reported a pretax loss of -55.49M and -55.53M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, SpectraCure AB's stock has declined approximately 88.84% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.05.

Over the twelve months ended June 30, 2026, SpectraCure AB generated - - in revenue and converted that into -55.53M in net income, yielding earnings per share of -0.08. EBITDA reached -24.04M, while operating income came in at -54.04M.

As of June 30, 2026, SpectraCure AB holds 7.63M in cash and equivalents against 8.91M in total debt, resulting in a net debt position of -7.63M. Total book value stands at 93.58M, with working capital of -2.69M providing operational flexibility.

SpectraCure AB produced -32.14M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -18.84M in capital expenditures, free cash flow totaled -50.99M - equivalent to -0.07 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -166.84: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -157.32, meaning SpectraCure AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

SpectraCure AB's most recent stock split took place on July 16, 2026.

As of June 30, 2026, SpectraCure AB has an Altman Z-Score of -24.76, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.